Intravacc, CimCure partner on cancer, COVID-19 vaccines

By The Science Advisory Board staff writers

July 1, 2020 -- Intravacc has entered a strategic partnership with CimCure for in-licensing of CimCure's iBoost technology for cancer immunotherapy vaccines and a COVID-19 vaccine.

Under the agreement, Intravacc will have access to iBoost technology for the development of new cancer immunotherapy vaccines in mutually agreed upon countries. The iBoost technology was developed at Amsterdam University Medical Center (UMC) by Arjan Gfiffioen, PhD, professor of experimental oncology and chief scientific officer at CimCure.

The technology elicits antibody responses against tumor vasculature to overcome drug resistance and the limitations of current methods for inducing antibody responses. Treatment with iBoost has long-term efficacy and is cost effective. CimCure has demonstrated proof-of-concept with several preclinical models.

Additionally, Intravacc and CimCure will participate in the joint development of a COVID-19 vaccine using the iBoost technology. This research is enabled by a $1.4 million award to CimCure/Amsterdam UMC from Health Holland, an investment organization of the Ministry of Economic Affairs.

With this collaboration, CimCure will focus on the design and preclinical validation of three different types of COVID-19 vaccine candidates, while Intravacc will be responsible for vaccine process development, pilot production of the candidate for clinical development, and a phase I clinical trial.

Intravacc, Versatope to develop universal flu vaccine
Dutch vaccine developer Intravacc and biotechnology firm Versatope have signed an agreement to collaborate on a universal influenza vaccine.
Intravacc forms public-private partnership for intranasal COVID-19 vaccine
Intravacc announced that it is partnering with Wageningen Bioveterinary Research and Utrecht University for the development of an intranasal vaccine against...
Intravacc, EpiVax partner for COVID-19 vaccine
Intravacc and EpiVax have entered a collaborative agreement to further develop a novel vaccine against COVID-19 based on Intravacc's proprietary outer...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter